Document Detail

Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention?
MedLine Citation:
PMID:  17660157     Owner:  NLM     Status:  MEDLINE    
Serum cardiac enzyme elevation after percutaneous coronary intervention (PCI), a relatively common complication, is a prognostic determinant of long-term outcome in patients who undergo these procedures. Statins are postulated to reduce such complications. This study investigated the short-term effects of pravastatin on serum creatine kinase myocardial isoform (CK-MB) and serum cardiac troponin I (cTpI) levels after elective PCI. Of 93 patients studied, 72 (77.4%) were men, and 21 (22.6%) were women (mean age, 58.9+/-11.0 y). Patients were randomly divided into 3 groups before they underwent elective PCI. Preoperatively, group 1 patients (n=30) received pravastatin 10 mg/d, and group 2 patients (n=29) received pravastatin 40 mg/d. Control group patients (n=34) received no lipid-lowering medication. Serum CK-MB and serum cTpI levels were measured preoperatively and then again at 6, 24, and 36 h postoperatively. Demographic features of patients and characteristics of the PCI procedure, including number of vessels/lesions and duration and number of inflations, did not differ among groups (P>.05). Mean serum CK-MB and serum cTpI levels were significantly increased after PCI in all patients (P<.001). When compared with control group patients, those given pravastatin did not experience significantly lowered postprocedural serum CK-MB or serum cTpI levels (P>.05). Preprocedural pravastatin therapy at dosages of 10 mg/d and 40 mg/d seems inadequate for preventing serum cardiac enzyme elevations during short-term follow-up after PCI. Additional research on this topic is recommended.
Huseyin Bozbas; Aylin Yildirir; Serdar Mermer; Didem Konas; Ilyas Atar; Alp Aydinalp; Bulent Ozin; Mehmet E Korkmaz; Haldun Muderrisoglu
Related Documents :
7506627 - Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological st...
7957327 - The value of ca 125 measurement before second-look laparotomy in patients with ovarian ...
7054877 - Ventricular cardiac arrhythmias during anesthesia: feasibility of preoperative recognit...
17170527 - Is a raised ca 19-9 level diagnostic for a cholangiocarcinoma in patients with no histo...
18039017 - Palmar erythema.
22426767 - Percutaneous closure of the left atrial appendage to prevent ischaemic stroke in patien...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Advances in therapy     Volume:  24     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2007 May-Jun
Date Detail:
Created Date:  2007-07-30     Completed Date:  2007-09-19     Revised Date:  2007-09-28    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  493-504     Citation Subset:  T    
Department of Cardiology, Faculty of Medicine, Baskent University, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Analysis of Variance
Angioplasty, Transluminal, Percutaneous Coronary* / adverse effects
Cardiomyopathies / enzymology,  etiology,  prevention & control
Creatine Kinase, MB Form / blood*,  drug effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*,  therapeutic use
Middle Aged
Pravastatin / pharmacology*,  therapeutic use
Troponin I / blood*,  drug effects
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Troponin I; 81093-37-0/Pravastatin; EC Kinase, MB Form

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hemostatic effects of microporous polysaccharide hemosphere in a rat model with severe femoral arter...
Next Document:  Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma.